Page last updated: 2024-10-25

cyproheptadine and Dengue Hemorrhagic Fever

cyproheptadine has been researched along with Dengue Hemorrhagic Fever in 1 studies

Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.

Research Excerpts

ExcerptRelevanceReference
"Rupatadine was previously shown to reduce endothelial dysfunction in vitro, reduced vascular leak in dengue mouse models and to reduce the extent of pleural effusions and thrombocytopenia in patients with acute dengue."9.51Efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever in patients with acute dengue: A randomised, double blind, placebo-controlled trial. ( Dissanayake, H; Gangani, C; Gomes, L; Gunasinghe, D; Idampitiya, D; Jayarathna, G; Jeewandara, C; Mahapatuna, SD; Malavige, GN; Narangoda, E; Ogg, GS; Perera, Y; Prathapan, S; Sahabandu, P; Vimalachandran, V; Wanigatunga, C; Wickramanayake, S; Wijewickrama, A, 2022)
"Rupatadine was previously shown to reduce endothelial dysfunction in vitro, reduced vascular leak in dengue mouse models and to reduce the extent of pleural effusions and thrombocytopenia in patients with acute dengue."5.51Efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever in patients with acute dengue: A randomised, double blind, placebo-controlled trial. ( Dissanayake, H; Gangani, C; Gomes, L; Gunasinghe, D; Idampitiya, D; Jayarathna, G; Jeewandara, C; Mahapatuna, SD; Malavige, GN; Narangoda, E; Ogg, GS; Perera, Y; Prathapan, S; Sahabandu, P; Vimalachandran, V; Wanigatunga, C; Wickramanayake, S; Wijewickrama, A, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Malavige, GN1
Jeewandara, C1
Wijewickrama, A1
Gunasinghe, D1
Mahapatuna, SD1
Gangani, C1
Vimalachandran, V1
Jayarathna, G1
Perera, Y1
Wanigatunga, C1
Dissanayake, H1
Prathapan, S1
Narangoda, E1
Idampitiya, D1
Gomes, L1
Wickramanayake, S1
Sahabandu, P1
Ogg, GS1

Trials

1 trial available for cyproheptadine and Dengue Hemorrhagic Fever

ArticleYear
Efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever in patients with acute dengue: A randomised, double blind, placebo-controlled trial.
    PLoS neglected tropical diseases, 2022, Volume: 16, Issue:6

    Topics: Animals; Cyproheptadine; Dengue; Double-Blind Method; Humans; Incidence; Mice; Severe Dengue; Treatm

2022